HUA HAN BIO PHARM. - Chance auf 100 bis 200% - 500 Beiträge pro Seite

[baluweb]

Folgender Wert scheint mir äußerst interessant zu sein:

HUA HAN BIO PHARM.

WKN: 726123
Symbol: HUI
ISN: KYG4638Y1008

Der Aktionär sieht die Chancen wie folgt:

100 bis 200 Prozent
Der Branchendurchschnitt wird dreimal teuerer bezahlt, da sollte bei diesem profitablen chinesischen Pharmawert doch eine Kursverdoppelung möglich sein.

Die Experten von Global Biotech Daily zitieren die lokalen Analysten von DBS Vickers, die die Aktie von Hua Han Bio-Pharma (WKN 726123) zum Kauf empfehlen. Im laufenden Jahr soll der Gewinn 124 Millionen Hongkong-Dollar erreichen und für das nächste Jahr wird er auf 153 Millionen geschätzt, was einem KGV von weniger als 5 entspricht. Der Branchendurchschnitt wird dagegen mit einer Gewinnvielfachen von 15 bewertet. Selbst wenn Hua Han also nur ein KGV von 10 erreicht, würden sich die Papiere im Wert verdoppeln. Allerdings sollten die mutigen Anleger ihre Orders in Berlin streng limitieren. Hua Han bietet vor allem gynäkologische Medizin und Gesundheitsprodukte für Frauen in China an. 2005 kamen mit der 93-prozentigen Beteiligung an DCX Pharmaceutical ein Pharmaunternehmen mit einer länger als hundertjährigen Geschichte und elf Produkten dazu.

Hört sich m.E. sehr gut an.

Gruß.

balu

[baluweb]

[baluweb]

Der Wert wird an der Börse in Hong Kong gehandelt und hat dort heute 9,24% zugelegt.

Der aktuelle Kurs ist bei 1,3 HK$ entsprechend 0,136 €.

Das bietet m.E. einen guten Einstiegswert. Ich empfehle jedoch nur mit limitierten Ordern zu kaufen. Keinesfalls unlimitiert!

Ein fairer Einstiegswert ist m.E. bis 0,142 €.

Gruß.

balu

[baluweb]

Investment Service Centre

Listed Companies Information


HUA HAN<00587> - Results Announcement

Hua Han Bio-Pharmaceutical Holdings Limited announced on 20/03/2006:
(stock code: 00587 )
Year end date: 30/06/2006
Currency: HKD
Auditors' Report: N/A
Interim report reviewed by: Audit Committee

(Unaudited )
(Unaudited ) Last
Current Corresponding
Period Period
from 01/07/2005 from 01/07/2004
to 31/12/2005 to 31/12/2004
Note ('000 ) ('000 )
Turnover : 302,435 324,588
Profit/(Loss) from Operations : 83,224 66,782
Finance cost : (5,501) (3,584)
Share of Profit/(Loss) of
Associates : N/A (435)
Share of Profit/(Loss) of
Jointly Controlled Entities : N/A N/A
Profit/(Loss) after Tax & MI : 61,472 50,684
% Change over Last Period : +21.3 %
EPS/(LPS)-Basic (in dollars) : 0.071 0.077
-Diluted (in dollars) : 0.070 0.074
Extraordinary (ETD) Gain/(Loss) : N/A N/A
Profit/(Loss) after ETD Items : 61,472 50,684
Interim Dividend : NIL NIL
per Share
(Specify if with other : N/A N/A
options)

B/C Dates for
Interim Dividend : N/A
Payable Date : N/A
B/C Dates for (-)
General Meeting : N/A
Other Distribution for : N/A
Current Period

B/C Dates for Other
Distribution : N/A

Remarks:

1. Accounting Policies

The condensed consolidated interim financial statements have been prepared
in accordance with Hong Kong Accounting Standard ("HKAS") 34 "Interim
Financial Reporting". The accounting policies and basis of preparation
adopted in the preparation of the interim financial statements are the
same as those used in the annual financial statements for the year ended
30 June 2005, except in relation to the following new and revised Hong
Kong Financial Reporting Standards ("HKFRSs", which also include HKASs and
Interpretations) that affect the Group and are adopted for the first time
for the current period's financial statements:

HKAS 17 Leases
HKAS 36 Impairment of Assets
HKFRS 3 Business Combinations

A. HKAS 17 Leases
In prior periods, leasehold land and buildings held for own use were
stated at cost or valuation less accumulated depreciation and any
impairment losses.

Upon the adoption of HKAS 17, the Group's leasehold interest in land and
buildings is divided into leasehold land and leasehold buildings. The
Group's leasehold land is classified as an operating lease, because the
title of the land is not expected to pass to the Group by the end of the
lease term, and is reclassified from fixed assets to prepaid land
premiums/land lease payments, while leasehold buildings continue to be
classified as part of property, plant and equipment. Prepaid land premiums
for land lease payments under operating leases are initially stated at
cost and subsequently amortised on the straight-line basis over the lease
term. When the lease payments cannot be allocated reliably between the
land and building elements, the entire lease payments are included in the
cost of the land and buildings as a finance lease in property, plant and
equipment.

This change in accounting policy has had no effect on the condensed
consolidated income statement and retained earnings. The comparatives on
the condensed consolidated balance sheet for the year ended 30 June 2005
have been restated to reflect the reclassification of leasehold land.

B. HKAS 36 - Impairment of Assets and HKFRS 3 - Business Combinations

In prior years, goodwill arising on acquisitions was capitalised and
amortised on the straight-line basis over its estimated useful life and
was subject to impairment testing when there was any indication of
impairment. Negative goodwill was carried in the balance sheet and was
recognised in the consolidated income statement on a systematic basis over
the remaining average useful life of the acquired depreciable/amortisable
assets, except to the extent it related to expectations of future losses
and expenses that were identified in the acquisition plan and that could
be measured reliably, in which case, it was recognised as income in the
consolidated income statement when the future losses and expenses were
recognised.

Upon the adoption of HKAS 36 and HKFRS 3, goodwill arising on acquisitions
is no longer amortised but subject to an annual impairment review (or more
frequently if events or changes in circumstances indicate that the
carrying value may be impaired). Any impairment loss recognised for
goodwill is not reversed in a subsequent period.

Any excess of the Group's interest in the net fair value of the acquirees'
identifiable assets, liabilities and contingent liabilities over the cost
of the acquisition of subsidiaries and associates (previously referred to
as "negative goodwill"), after reassessment, is recognised immediately in
the income statement.

The transitional provisions of HKFRS 3 have required the Group to
eliminate at 1 July 2005 the carrying amounts of accumulated amortisation
with a corresponding entry to the cost of goodwill and to derecognise the
carrying amounts of negative goodwill against retained earnings.

Pursuant to HKFRS 3, the carrying amount of negative goodwill in the
balance sheet as at 1 July 2005 of HK$35,897,000 was derecognised by way
of a corresponding adjustment to the opening retained profits as at 1 July
2005. In accordance with the transitional provisions of HKFRS 3,
comparative amounts have not been restated.

2. Turnover
Turnover represents the net invoiced value of goods sold,
after allowances for returns and trade discounts. All significant intra-
group transactions have been eliminated on consolidation.

3. Profit from operating activities
Profit from operating activities is arrived at after charging/(crediting):

For the six months ended
31 December
2005 2004
(Unaudited) (Unaudited)
HK$'000 HK$'000

Cost of inventories sold 100,779 167,301
Staff costs 12,816 11,238
Depreciation 4,863 3,021
Amortisation of prepaid land premiums 197 142
(Gain)/ loss on disposal of fixed assets 26 (115)
Amortisation of intangible assets, net 1,124 454

Interest income on bank balances (3,290) (2,452)
======= =======


4. Basic and diluted earnings per share
The calculation of basic and diluted earnings per share of HK$0.1 each
of the Company (each a "Share") for the Period are as follows:

For the six months ended
31 December
2005 2004
(Unaudited) (Unaudited)
Net profit from ordinary activities attributable to shareholders for
the purpose
of calculating basic earnings per Share (HK'000)
61,472 50,684

Increase in net profit for deemed conversion of potential ordinary Shares
(HK'000)
5 74
------- -------

Adjusted profit for the purpose of calculating dilutive earnings per Share
(HK$'000)

61,477 50,758
======= =======

Number of Shares
Weighted average number of ordinary Shares
for the purpose of calculating basic earnings per Share ('000)
870,765 660,824

Effect of dilutive potential ordinary Shares ('000) (Note)
3,287 22,559
------- -------

Weighted average number of ordinary Shares for the purpose of
calculating diluted earnings per Share ('000)
874,052 683,383
======= =======

Note:

Number of ordinary Shares deemed to be issued on full conversion of
convertible bonds and to be issued at nil consideration on exercise of all
outstanding share options are 262,000 Shares (2004: 11,073,000 Shares) and
3,025,000 Shares (2004: 11,486,000 Shares) respectively.

[baluweb]

Stock Code an der Börse Hong Kong: 587!

Link zur Börse Hong Kong: http://www.hkex.com.hk/invest/index.asp?id=company/quotemenu…

[baluweb]

Um weitere Informationen wir den Quartalsbericht zu lesen, bitte folgenden Link benutzen:

http://www.hkex.com.hk/listedco/listconews/sehk/search.asp

und dort den Stock-Code 587 eingeben. Ihr könnt dann die einzelnen Information abrufen.

Gruß.

balu

[baluweb]

Interessant auch, dass man sich im Management anscheined um korrektes Verhalten bemüht:

Investment Service Centre

Listed Companies Information


HUA HAN<00587> - Unusual price & volume movements

The Stock Exchange has received a message from Hua Han
Bio-Pharmaceutical Holdings Limited which is reproduced as follows:-

"The following statement is made at the request of The Stock Exchange of
Hong Kong Limited ("Stock Exchange").

The directors ("Directors") of the Company have noted the recent increase
in trading volume and price of the shares of the Company and wish to state
that, they are not aware of any reasons for such increase in trading
volume and price of the shares.

The Directors also confirm that there are no negotiations or agreements
relating to intended acquisitions or realisations which are discloseable
under rule 13.23 of the Rules Governing the Listing of Securities on the
Stock Exchange ("Listing Rules"), neither are the Directors aware of any
matter discloseable under the general obligation imposed by rule 13.09 of
the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the board of Hua Han Bio-Pharmaceutical Holdings
Limited, the Directors of which individually and jointly accept
responsibility for the accuracy of the above statement.

As at the date of this announcement, the board of Directors comprises Mr.
Zhang Peter Y., Mr. Xu Peng, Mr. Deng Jie, Mr. Long Xian Feng and Mr. Wu
Xian Peng as executive directors, Mr. Wee Ee Lim (Mr. Tarn Sien Hao as his
alternate) and Mr. Han Ah Kuan (Mr. Ong Sian Hin as his alternate) as non
-executive directors, and Professor Kung Hsiang Fu, Professor Tso Wung Wai
and Mr. Hon Yiu Ming Matthew as independent non-executive directors.


For and on behalf of
Hua Han Bio-Pharmaceutical Holdings Limited


Name: Deng Jie
Title: Executive Director

31 March 2006"




Für mich ein klares Zeichen!

Gruß.

balu

[baluweb]

Übrigens: die Meldung von Der Aktionär ist vom 03.04.2006! Also nach dem bereits erfolgten Kursanstieg. Und dass die mit ihrer Einschätzung nicht so verkehrt liegen, zeigt m.E. der heutige Kursverlauf!

Gestartet war der Kurs bei 1,19 HK$, Tageshoch war 1,35 HK$, Schlusskurs dann 1,30 HK$!



Gruß.

balu

[baluweb]

[baluweb]

[trendman]

Antwort auf Beitrag Nr.: 21.099.678 von baluweb am 06.04.06 11:31:33

Kann nichts finden im Aktionär? Welche Ausgabe Nr.?

[baluweb]

Antwort auf Beitrag Nr.: 21.100.915 von trendman am 06.04.06 12:37:32

Schau mal hier nach:

http://www.deraktionaer.de/xist4c/web/100-bis-200-Prozent_id…

Gruß.

balu

[Cromagnon]

Bei Hua Hun sollte sich ein risikobewusster Anleger die Bilanz anschauen und danach entscheiden. Dies Unternehmen schiebt schon länger viel Cash vor sich her und hat trotzdem Schulden.

[baluweb]

Heute leichter Kursverfall bei relativ geringen Volumen!

Last: 1,26
Volumen: 1,568 Mio
High: 1,30
Low: 1,26

Gruß.

balu